It was among the biggest grants in the agency’s young history and was approved without a scientific review, leading the agency’s chief scientific officer to stage down. If I could do that one grant once more, I’d differently do it, stated Gimson, adding that the agency has since examined its review procedure. Gimson said the company is still searching for a new chief scientific officer and doesn’t believe the criticism coming from within the medical community will hamper efforts to displace those who’ve resigned. Agency officials as of this week’s meeting are also scheduled to discuss – – but take no formal actions on – – proposed changes to how the condition divvies up grant awards between research, commercialization and prevention initiatives to bring new medications to market.Related StoriesDiabetes drug liraglutide ineffective in individuals with advanced heart failureStudy finds high prevalence of dehydration in the elderly living in UK care homesMayo Clinic investigators discover novel system associated with diabetes riskAs reported in the Canadian Medical Association Journal, sufferers treated with the closed-loop program got their glucose regulated with subcutaneous insulin infusion coupled with subcutaneous miniboluses of glucagon shipped by two infusion pumps, as dependant on a sophisticated mathematical algorithm. Sufferers who received subcutaneous insulin infusion only , had access to their finger stay glucose measurement and altered their insulin delivery based on the carbohydrate articles of their evening meal and bedtime snack.